Abstract:Modulation of the renin-angiotensin-aldosterone system is a foundation of therapy for cardiovascular and kidney diseases. Excess aldosterone plays an important role in cardiovascular disease, contributing to inflammation, fibrosis, and dysfunction in the heart, kidneys, and vasculature through both genomic and mineralocorticoid receptor (MR)-mediated as well as nongenomic mechanisms. MR antagonists have been a key therapy for attenuating the pathologic effects of aldosterone but are associated with some side effects and may not always adequately attenuate the nongenomic effects of aldosterone. Aldosterone is primarily synthesized by the CYP11B2 aldosterone synthase enzyme, which is very similar in structure to other enzymes involved in steroid biosynthesis including CYP11B1, a key enzyme involved in glucocorticoid production. Lack of specificity for CYP11B2, off-target effects on the hypothalamic-pituitary-adrenal axis, and counterproductive increased levels of bioactive steroid intermediates such as 11-deoxycorticosterone have posed challenges in the development of early aldosterone synthase inhibitors such as osilodrostat. In early-phase clinical trials, newer aldosterone synthase inhibitors demonstrated promise in lowering blood pressure in patients with treatment-resistant and uncontrolled hypertension. It is therefore plausible that these agents offer protection in other disease states including heart failure or chronic kidney disease. Further clinical evaluation will be needed to clarify the role of aldosterone synthase inhibitors, a promising class of agents that represent a potentially major therapeutic advance.

Research and Development of Aldosterone Inhibitors

Structural Basis for Ligand Recognition and Functional Selectivity at Angiotensin Receptor.

A Patent Review of Aldosterone Synthase Inhibitors (2014-Present)

Research and Development of the New Drugs Acting on Angiotensin II Receptor

Aldosterone and aldosterone synthase inhibitors in cardiorenal disease

Structural Insights into Angiotensin Receptor Signaling Modulation by Balanced and Biased Agonists.

Structural Insights into Ligand Recognition and Activation of Angiotensin Receptors.

Emerging trends in small molecule inhibitors targeting aldosterone synthase: A new paradigm in cardiovascular disease treatment

Small molecule angiotensin converting enzyme inhibitors: A medicinal chemistry perspective

Advances in Research into Cardiovascular Effect of Angiotensin II Type 2 Receptor

Aldosterone receptor antagonists: biology and novel therapeutic applications

Development of Novel Dual Angiotesin Ⅱ and Endothelin Receptor Antagonists

Status of Angiotensin-converting Enzyme Inhibitors (ACEI) and Progress of the Research on ACEI from Natural Sources

Research Progress of Nonpeptide Renin Inhibitors

Advances in Research on Structure-activity Relationship of Selective AngiotensinⅡ AT_2 Receptor Agonists

Development of Novel Dual Angiotesin II and Endothelin Receptor Antagonists

[Research progress on the cardiorenal protection of non-steroid mineralocorticoid receptor antagonists in patients with chronic kidney disease]

Research Progress in Finerenone in Cardiovascular Diseases

Synthesis and biological activity evaluation of AT1 angiotensin II receptor antagonists of dibenzimidazoles with N-phenyl-1 H-pyrrole

Design of Novel Thiazole Bearing Pyrazole Derivatives and Their Dual Activities as ACE Inhibitors and Calcium Channel Blockers in Cardiovascular Disease

Advances in the structural basis for Angiotensin-1 converting enzyme (ACE) inhibitors